Navigation Links
GeoVax to Exhibit at the 2009 BIO International Convention
Date:5/11/2009

Dr. Harriet Robinson to Host HIV Vaccine Panel Discussion

ATLANTA, May 11 /PRNewswire-FirstCall/ --

    WHAT:    GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based,
             publicly traded biopharmaceutical company developing human
             vaccines for diseases caused by HIV-1 (Human Immunodeficiency
             Virus) and other infectious agents to share their strategy for
             the future and plans to expand preventative trials, currently in
             Phase 2a, to proof-of-concept trials in 'at risk' humans and
             move therapeutic trials from non-human primate models to HIV-1
             virus infected individuals.

             Dr. Harriet Robinson to moderate "HIV/AIDS Vaccines: Preventative
             and Therapeutic Approaches to a Global Pandemic"

    WHERE:   2009 BIO International Convention
             Georgia Pavilion (Booth #2817)
             Georgia World Congress Center
             Atlanta, GA

    WHEN:    May 18-21, 2009
             "HIV/AIDS Vaccines: Preventative and Therapeutic Approaches to a
             Global Pandemic" Thursday, May 21, 10-11 a.m., Room B309

    WHO:     Robert McNally, Ph.D., chief executive officer and president
             Mark Reynolds, chief financial officer
             Harriet Robinson, PhD, vice president of research and development
             and developer of the GeoVax vaccine

    WHY:     HIV Vaccine Awareness Day coincides with the opening of the
             conference on May 18, and Sir Elton John delivering a keynote
             address to include how biotechnology is influencing treatment and
             prevention of the diseases.  GeoVax is looking forward to sharing
             with interested partners, investors and media its progress in
             clinical trials during the last six months and its strategy for
             the future.


'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. GeoVax Labs, Inc. Announces First Quarter Financial Results
2. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
3. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
4. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
5. GeoVax to Present at the BIO CEO & Investor Conference 2009
6. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Presents Data at AIDS Vaccine 2008 Conference
9. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
10. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
11. GeoVax Further Strengthens Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating unique ... time adjusting, tweaking and testing virtual models and 3D ... judging. , “I enjoyed being involved as a judge,” ... entries showed a commendable range exploring the technical capabilities ... medium and the creativity of the contestants.” , Array ...
(Date:10/1/2014)... 30, 2014 New applications of structures ... have evolved in nature over millennia are featured in ... for applications in biophotonics in the October issue ... journal is published by SPIE, the international society for ... of the peer-reviewed articles are accessible via open access. ...
(Date:10/1/2014)... TeselaGen Biotechnology has received ... expand their bioCAD/CAM software suite, which uses synthetic ... Small Business Innovation Research Phase II grant will be ... license from the Lawrence Berkeley National Laboratory. j5 was ... LBNL laboratory that develops alternative fuel technologies for the ...
(Date:10/1/2014)... 2014 Industry leaders from ... engage around the theme, ,Commercial Opportunities in the Era ... Elsevier , a world-leading provider of ... host a gathering of some of the industry,s most ... healthcare today and in the future. The ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... NicOx S.A.,(NYSE Euronext Paris: COX) today announced ... the commercial manufacture and supply of naproxcinod ... is NicOx, lead,investigational product and the first ... of,anti-inflammatory agents, which recently achieved positive results ...
... Sinovac Biotech Ltd. (NYSE Alternext,US: SVA), a leading provider of ... Fengtai District in the City of Beijing suspended,the use of ... of the death of a minor in the Fengtai District ... vaccine two days prior. , ...
... market research firm SharpBrains, will lead a webinar discussing the Top ... providers. , ... San Francisco, CA (PRWEB) December 2, ... World Economic Forum,s Council on the Challenges of Gerontology, will lead ...
Cached Biology Technology:NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Sinovac Releases Statement on Healive Vaccine Suspension 2Top 10 Cognitive Fitness Events of 2008 to be Unveiled at SharpBrains' Webinar 2Top 10 Cognitive Fitness Events of 2008 to be Unveiled at SharpBrains' Webinar 3
(Date:10/1/2014)... microbes that thrive in the deserts, rainforests, prairies and ... beneath New York City,s Central Park, according to a ... the University of Colorado Boulder. , The research ... Park,s 843 acres and discovered a stunning diversity of ... before. , Only 8.5 percent to 16.2 percent ...
(Date:9/30/2014)... by the Ocean Health Index rates the Earth,s ... health. In addition, for the first time, the ... regions beyond national jurisdiction (high-seas areas) all ... biodiversity and providing sustainable food sources. , In ... partnership led by scientists from UC Santa Barbara,s ...
(Date:9/30/2014)... scientists and engineers, led by Clemson University associate ... million grant from the U.S. Department of Energy,s ... a direct positive impact on South Carolina in ... radioactive contaminants. , "Understanding the scientific and engineering ... aspects of nuclear technologies is imperative if South ...
Breaking Biology News(10 mins):Microbes in Central Park soil: If they can make it there, they can make it anywhere 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 3Rating the planet's oceans 2Rating the planet's oceans 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2
... (March 5, 2013) Researchers have discovered that deleting a ... on a high fat diet, a finding they believe may ... induces obesity these mice don,t get fat," said Prof. James ... research for Obstetrics and Gynecology at the University of Colorado ...
... Center scientists report the first successful blocking of tumor development in ... my knowledge, this is the first time that a mouse model ... which the formation of the tumor from beginning to end can ... of the tumor," said Dr. Luis Parada , chair of ...
... 2013) Researchers at the University of Minnesota,s ... cellular reprogramming to generate stem cells capable of ... Muscular Dystrophy (DMD). The research, which ... pluripotent stem cell technology and genetic correction to ...
Cached Biology News:Researchers discover gene that causes obesity in mice 2UT Southwestern scientists make mouse model of human cancer, demonstrate cure 2UT Southwestern scientists make mouse model of human cancer, demonstrate cure 3U of M researchers utilize genetically corrected stem cells to spark muscle regeneration 2U of M researchers utilize genetically corrected stem cells to spark muscle regeneration 3
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
...
... used in conjuction with Annexin V-FITC to ... stages of apoptosis (Annexin V positive, PI ... stages of apoptosis or already dead (Annexin ... in the orange range of the spectrum ...
... were cultured in RPMI 1640 with 2 mM ... growth. In order to keep the antigens ... acetone-methanol. The cells are arrayed on a ... wells surface specifically treated to enhance cellular attachment ...
Biology Products: